Last reviewed · How we verify
ReCell
At a glance
| Generic name | ReCell |
|---|---|
| Also known as | autologous cell harvesting |
| Sponsor | Wake Forest University Health Sciences |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Skin Color Matching in Head and Neck Reconstructive Surgery (NA)
- Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells (NA)
- ReCell® Combined With Meshed Skin Graft in the Treatment of Acute Burn Injuries (NA)
- RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients (PHASE4)
- CONTINUED ACCESS PROTOCOL: Demonstration of the Safety and Effectiveness of ReCell® Combined With Meshed Skin Graft for Reduction of Donor Area in the Treatment of Acute Burn Injuries (NA)
- RES® Prepared With RECELL® Compared to Standard of Care Dressings of Partial-thickness Burns in Ages 1-16 Years (NA)
- RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction (NA)
- Continued Access to the Recell® Device for Treatment of Acute Burn Injuries
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ReCell CI brief — competitive landscape report
- ReCell updates RSS · CI watch RSS
- Wake Forest University Health Sciences portfolio CI